Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

3Â÷ ÀÇ·á±â°ü¿¡¼­ Helicobacter pylori Á¦±ÕÀÇ ¼ºÀû: Áúȯ°ú Åõ¿©µÈ ¾àÁ¦, Åõ¿© ±â°£¿¡ µû¸¥ Á¦±ÕÀÇ ¼ºÀû°ú Á¦±Õ ÈÄ Àç°¨¿°¿¡ ´ëÇÑ Á¶»ç Eradication Rate of Helicobacter pylori according to the Diseases and Therapeutic Regimens, and Reinfection Rate after Successful Eradication in a Tertiary Clinic

´ëÇѼÒÈ­±âÇÐȸÁö 2003³â 41±Ç 1È£ p.1 ~ 8
Á¤¿ìö, Á¶¿µ¼®, Á¤Á¤Á¶, ÀÌÀμ®, ±è»ó¿ì, ¾çÁø¸ð, ÃÖ¸í±Ô, Á¤ÀνÄ, ¹ÚµÎÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
Á¤¿ìö ( Chung Woo-Chul ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Á¶¿µ¼® ( Cho Young-Seok ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤Á¤Á¶ ( Jeong Jeong-Jo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÀμ® ( Lee In-Seok ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è»ó¿ì ( Kim Sang-Woo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¾çÁø¸ð ( Yang Jin-Mo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖ¸í±Ô ( Choi Myung-Gyu ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¤ÀνĠ( Chung In-Sik ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚµÎÈ£ ( Park Doo-Ho ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

¸ñÀû: H. pylori Á¦±ÕÀ» À§ÇÑ ¾à¹°¿ä¹ýÀÇ Àû¿ë°ú ¼±Åÿ¡ °üÇÑ ¹®Á¦´Â ¾ÆÁ÷µµ ³í¶õÀÇ ¿©Áö°¡ ¸¹°í °°Àº ¿ä¹ýÀÌ¶óµµ º¸°íÀÚ¸¶´Ù Â÷ÀÌ°¡ ¸¹´Ù. º» ¿¬±¸¿¡¼­´Â 3Â÷ ÀÇ·á±â°ü¿¡¼­ ½ÃÇàÇÑ H. pylori Á¦±ÕÀÇ ¼ºÀû¿¡ ´ëÇØ °ËÅäÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: ÃÖ±Ù 6³â»çÀÌ¿¡ °­³²¼º¸ðº´¿ø ¼ÒÈ­±â³»°ú ¿Ü·¡¿¡ ³»¿øÇÏ¿© Á¦¹ý¿ä¹ýÀ» ½ÃÇàÇÑ È¯ÀÚ¸¦ ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ¿´´Ù. Á¦±ÕÀÇ ¼º°ø ¿©ºÎ´Â ¿ä¼ÒÈ£±â°Ë»ç¸¦ ±âº»À¸·Î ÇÏ°í, Áõ»óÀÌ Àְųª ¼ÒÈ­¼º ±Ë¾çÀÌ ÀÖ¾ú´ø ȯÀÚ´Â ³»½Ã°æ°Ë»ç¸¦ Ãß°¡·Î ½Ç½ÃÇÏ¿© ÆÇ´ÜÇÏ¿´´Ù. 6°³¿ù¸¶´Ù ¿ä¼ÒÈ£±â°Ë»ç³ª ³»½Ã°æ°Ë»ç¸¦ ½Ç½ÃÇÏ¿© ÃßÀû °æ°ú°üÂûÇÏ¿´´Ù.

°á°ú: ÃßÀû°Ë»ç¸¦ ¿Ï·áÇÑ 389¸íÀ» ´ë»óÀ¸·Î ÇÏ¿´´Ù. Á¦±Õ ¼º°ø·üÀº 79.2%¿´´Ù. Áúȯ¿¡ µû¸¥ Á¦±Õ ¼ºÀûÀº À§¿° 79.3%, À§±Ë¾ç 80.6%, ½ÊÀÌÁöÀå±Ë¾ç 84.7% ·Î Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾Ò´Ù. ¾àÁ¦¿¡ µû¸¥ Â÷ÀÌ´Â lansporazoleÀ» Æ÷ÇÔÇÏ°í 2°¡ÁöÀÇ Ç×»ýÁ¦¸¦ 7ÀÏ°£ »ç¿ëÇÑ ±º(79.4%)°ú omeprazoleÀ» Æ÷ÇÔÇÑ ±º(72.0%) »çÀÌ¿¡ À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. Á¦±Õ¿ä¹ýÀ» ½ÃÇàÇÑ ±â°£¿¡ µû¶ó omeprazole°ú 2°¡Áö Ç×»ýü¸¦ »ç¿ëÇÏ¿© 7ÀÏ°£ º¹¿ëÇÑ ±ºÀº 72.0%, 10ÀÏ°£ º¹¿ëÇÑ ±ºÀº 84.9%,
14ÀÏ°£ º¹¿ëÇÑ ±ºÀº 88.1%¿¡¼­ ¼º°øÀûÀ¸·Î Á¦±ÕµÇ¾ú´Ù. 10ÀÏ°ú 14ÀÌ°£ º¹¿ëÇÑ ±ºÀÌ 7ÀÏ°£ º¹¿ëÇÑ ±º¿¡ ºñÇØ Åë°èÇÐÀûÀ¸·Î À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù. 1Â÷ Á¦±Õ¿¡ ½ÇÆÐÇÑ 39¸íÀ» ´ë»óÀ¸·Î 2Â÷ ¼¼±ÕÀ» 4Á¦¿ä¹ýÀ¸·Î ½Ç½ÃÇÑ °á°ú, Á¦±Õ ¼º°ø·üÀº 76.9%¿´´Ù. 1³â ÀÌ»ó Á¦±ÕÀÌ È®ÀÎµÈ ÈÄ °æ°ú °üÂûÀ» ÇÑ 131¸íÀÇ È¯ÀÚ¿¡¼­ 11¸íÀÌ Àç°¨¿°µÇ¾ú´Ù. Àç°¨¿°ÀÌ ÀϾ ºñÀ²Àº 4.4%¿´´Ù.

°á·Ð: 3Â÷ ÀÇ·á±â°ü¿¡¼­ ½ÃÇàÇÏ°í ÀÖ´Â H. pyloriÀÇ Á¦¹ý¿ä¹ýÀº 79.2%ÀÇ ¼ºÀû¿¡ ºÒ°úÇÏ¿´À¸¸ç, Á¦±Õ¿¡ »ç¿ëµÈ ¾àÁ¦¿¡ µû¸¥ À¯ÀÇÇÑ Â÷ÀÌ´Â ¾ø¾ú´Ù. Á¦±Õ¿ä¹ýÀÇ ±â°£À» ´Ã¸®´Â °ÍÀÌ Á¦±Õ ¼ºÀûÀ» ³ôÀÌ´Â ¹æ¹ýÀ¸·Î »ý°¢µÈ´Ù.

Background/Aims: Controversies regarding the indications and regimens for the eradication of Helicobacter pylori (H. pylori) still exist. Failure rates have been reported to range from 5% to 10%. This study aimed to review the efforts for the eradication of H. pylori in a tertiary clinic. We assessed the eradication rates according to the diseases, therapeutic regimens, and duration of therapy. In addition, we examined the effectiveness of secondary regimens in patients who failed to respond to primary regimens and the reinfection rate after a successful eradication.

Methods: We investigated 389 patients with documented H. pylori infection between January 1996 and December 2001.

Results: The overall eradication rate was 79.2%. There were no significant differences in the eradication rates sccording to the diseases and therapeutic regimens. However, there was a significant difference according to the duration of therapy. Proton pump inhibitor (PPI)-based 10-day and 14-day regimens were superior to 7-day regimens. The eradication rate of secondary regimens in patients who failed to respond to primary regimens was 76.9%. The reinfection rate after a successful eradication was 4.4%.

Conclusion: These results suggest that PPI-based triple regimens with 10 or 14 days of duration should be considered as primary H. pylori eradication therapy.

Å°¿öµå

Helicobacter pylori; Á¦±Õ ¼º°ø·ü; Àç°¨¿°·ü; Helicobacter pylori; Eradicaiton rate; Reinfection rate;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS